Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

(2015) C. Gebhardt et al.   CLINICAL CANCER RESEARCH

Tumor-induced CD14+HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients

(2014) Zhitao Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

(2014) Andrea Acebes-Huerta et al.   Biomed Research International

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities

(2014) Cirino Botta et al.   Frontiers in Oncology

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

(2013) A. C. Chan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model

(2013) Haneen Nur et al.   PLoS One

The role of natural killer T cells in B cell malignancies

(2013) Ghasem Ghalamfarsa et al.   TUMOR BIOLOGY

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

(2012) J. Richter et al.   BLOOD

Current treatment strategies with lenalidomide in multiple myeloma and future perspectives

(2012) Alessandra Larocca et al.   Future Oncology

Myeloid-derived Suppressor Cells in Cancer Patients

(2012) Alberto J. Montero et al.   JOURNAL OF IMMUNOTHERAPY

Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

(2011) Melissa G Lechner et al.   Journal of Translational Medicine

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

(2011) M A Dimopoulos et al.   LEUKEMIA

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells

(2010) S. Nagaraj et al.   JOURNAL OF IMMUNOLOGY

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Treatment of Relapsed/Refractory Multiple Myeloma

(2009) Efstathios Kastritis et al.   SEMINARS IN HEMATOLOGY

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA